The YCC Administration provides infrastructure to promote cancer research activities of its 260 members, with a particular emphasis on facilitating transdisciplinary and translational research. The Administration supports the Director, Senior Leaders, Program Leaders, Shared Resources Directors and YCC Members in carrying out the YCC mission through effective management, centralized resources, and strategic planning. YCC Administrative responsibilities: ? Communicate between and among Center Director, Deputy, Associate and Assistant Directors,, Program Leaders, Shared Resource Directors and stakeholders within and outside the Institution; ? Develop and implement the YCC strategic plan in concert with the Center's leadership and integrate recommendations from standing and ad hoc advisory boards; ? Develop and coordinate research administration activities to support planning and evaluation, integrate and promote the collaborative, transdisciplinary and translational research activities of the YCC; ? Provide financial management of all YCC and CCSG funds and accounts;maintain fiduciary responsibility including preparing and maintaining annual operating,, capital and Shared Resource budgets;intra- and extramural research fund management;tracking Shared Resource usage;preparing grants, contracts and other financial reports; * Provide personnel and human resource services in support of YCC leadership and membership; * Manage Shared-Resources and provide financial oversight, data on usage patterns, and determine chargeback rate; * Manage YCC facilities, space, and equipment; * Manage and coordinate funding opportunities including intramural pilot project programs and other research project post award management; * Support and coordinate YCC membership application and review processes; * Manage and respond to research information technology and informatics needs; * Coordinate YCC committees;management of human resources, development, marketing, public affairs, and education programs.

Public Health Relevance

The administration is a key component of the YCC. A highly effective administration is of paramount importance for the YCC and its members to achieve their missions. The administration's chief priority is to ensure the effective execution of business, administrative, and financial operations such that the research activities of YCC members can flourish.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-35
Application #
8755649
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
35
Fiscal Year
2014
Total Cost
$243,781
Indirect Cost
$97,366
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40

Showing the most recent 10 out of 675 publications